Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PER2 | O15055 | 18/20 | 0.47 |
| ▸ | CRY1 | Q16526 | 16/20 | 0.43 |
| ▸ | CRY2 | Q49AN0 | 16/20 | 0.43 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9004363 | 0.89 | PER2 (0.52) | PER2CRY1CRY2 | |
| SCHEMBL8487228 | 0.78 | CRY1 (0.53) | PER2CRY1CRY2 | |
| SCHEMBL8489440 | 0.77 | HCRTR2 (0.37) | SLC18A3 | |
| SCHEMBL8489557 | 0.76 | PER2 (0.55) | PER2CRY1CRY2 | |
| SCHEMBL9004296 | 0.73 | PER2 (0.43) | PER2CRY1CRY2 | |
| SCHEMBL9004327 | 0.73 | PER2 (0.40) | PER2CRY1CRY2 | |
| SCHEMBL8491767 | 0.71 | PER2 (0.39) | PER2CRY1CRY2 | |
| SCHEMBL8488600 | 0.69 | PER2 (0.38) | PER2CRY1CRY2 | |
| SCHEMBL8487214 | 0.69 | PER2 (0.38) | PER2CRY1CRY2 | |
| SCHEMBL8491775 | 0.69 | PER2 (0.47) | PER2CRY1CRY2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0730586-A1 | 1,4,7,10-TETRAAZACYCLODODECANE DERIVATIVES, THEIR USE, PHARMACEUTICALS CONTAINING THEM AND PROCESS FOR THEIR PRODUCTION | SCHERING AKTIENGESELLSCHAFT (DE) | 1996-09-11 | — | — | EP | disclosed |
| WO-1995014678-A1 | 1,4,7,10-TETRAAZACYCLODODECANE DERIVATIVES, THEIR USE, PHARMACEUTICALS CONTAINING THEM AND PROCESS FOR THEIR PRODUCTION | SCHERING AKTIENGESELLSCHAFT (DE) | 1995-06-01 | — | — | WO | disclosed |